Genethon: green light from the ANSM to start a gene therapy trial for Duchenne.D

Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorisation from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular dystrophy with product GNT 004. This trial’s…

Details

Tackling ethics concerns regarding use of ‘carebots’ to assist older adults

A new analysis from North Carolina State University highlights the realistic pros and cons of apps and other technologies that use artificial intelligence (AI) to benefit older adults, including those facing dementia and cognitive decline. The work focuses on how these technologies can help older adults preserve their autonomy, and addresses ethical concerns that have…

Details

Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program. Dana-Farber is home to one of the largest and most respected treatment centers for patients with disorders…

Details

COVID-19 may deepen depression, anxiety, and PTSD among pregnant and postpartum women

Boston — Though childbirth is often anticipated with optimism and enthusiasm, approximately 10 to 20 percent of pregnant individuals also experience mental health challenges during the weeks immediately before and after birth. Depression, anxiety and trauma-related disorders can all be exacerbated by increased stress related to pregnancy and postpartum experiences. But it’s unknown how the…

Details

OHDSI awarded $10 MM FDA contract to monitor safety/effectiveness of vaccines, biologics

NEW YORK, NY (Dec. 1, 2020)–Researchers within the Observational Health Data Services and Informatics (OHDSI) community were recently awarded a $10 million contract from the U.S. Food and Drug Administration (FDA) to provide support to the Biologics Effectiveness and Safety (BEST) program, which was launched by the FDA Center for Biologics Evaluation and Research (CBER)…

Details